Human Reproduction, Vol 13, 1159-1162, Copyright © 1998 by Oxford University Press
M Bondanelli, MR Ambrosio, P Franceschetti, R Guerrini, A Valentini and EC degli Uberti
There is evidence that endogenous opioid peptides exert an inhibitory
effect on pituitary luteinizing hormone (LH) secretion both in animals and
in humans, by interacting with mu-opioid receptors. However, a role for
delta-opioid receptors in the regulation of gonadotrophin releasing hormone
(GnRH) secretion has recently been suggested. In the present study, we
evaluated the effect of the highly selective delta-opioid receptor agonist
deltorphin on the LH and follicle stimulating hormone (FSH) responses to
naloxone in six healthy fertile women during the luteal phase of the
menstrual cycle. Deltorphin infusion alone (7 microg/kg/min for 60 min) did
not significantly change the basal serum concentrations of LH in this group
of women. The intravenous (i.v.) bolus administration of naloxone (15 mg)
induced a significant (P < 0.001) increase in serum LH concentrations
(from a mean basal value of 4.24+/-1.10 IU/l to a peak of 13.27+/-1.8
IU/l). The LH response to naloxone was significantly (P < 0.001) blunted
by preinfusion of deltorphin (13.27+/- 1.80 IU/l versus 4.80+/-1.18 IU/l).
No significant changes in FSH concentrations were observed during
deltorphin, naloxone or deltorphin plus naloxone administration. These data
indicate that activation of delta-opioid receptors can reduce
naloxone-induced LH release, suggesting a possible role of delta receptors
in opioidergic modulation of LH secretion in women.
ARTICLES
Effect of delta-opioid receptor agonist deltorphin on circulating concentrations of luteinizing hormone and follicle stimulating hormone in healthy fertile women
Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, Italy.
![]()
CiteULike
Connotea
Del.icio.us What's this?